Vaccine developer stocks rise as flu activity escalates

Investing.com — Shares of vaccine developers, including Moderna (NASDAQ:) and CureVac, have seen an uptick in premarket trading on Monday as the seasonal flu activity intensifies across the United States. Moderna’s stock increased up to 3.4%, while CureVac’s shares jumped as much as 13%.

Other vaccine manufacturers also experienced a rise in their stock prices. Shares of Novavax (NASDAQ:) went up by 3.1%, and BioNTech (NASDAQ:) saw a 1.4% increase.

The Arkansas Department of Health’s most recent weekly report has indicated a significant rise in flu activity in the state. The report, which ended on Dec. 28, 2024, shows that flu activity has reached the “Very High” level of 11 on a 13-point scale. This is a noteworthy increase from the previous two weeks, which were classified as “High.” At the beginning of the month, the flu activity was reported as “Low.”

This is the first time a “Very High” ranking has been assigned since the flu season began on Sept. 30. The rise in flu activity is likely contributing to the increased interest in vaccine developer stocks.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.